Fumarate salt of 4-bromophenyl 1,4-diazabicyclo[3.2.2]nonane-4-carboxylate, crystalline forms thereof, preparation thereof and therapeutic use thereof

1. A fumarate salt of 4-bromophenyl 1,4-diazabicyclo-[3.2.2]nonane-4-carboxylate, selected from the group consisting of the crystalline polymorphic form I and the crystalline polymorphic form II.

2. The fumarate salt of 4-bromophenyl 1,4-diazabicyclo[3.2.2]nonane-4-carboxylate according to claim 1 , wherein it is in the crystalline polymorphic form I.

3. The fumarate salt of 4-bromophenyl 1,4-diazabicyclo[3.2.2]nonane-4-carboxylate according to claim 2 , the infrared spectrum of which exhibits at least three of the following characteristic absorption bands:

λ (cm −1 )

2953

2789

1735

1613

1488

 624.

4. The fumarate salt of 4-bromophenyl 1,4-diazabicyclo[3.2.2]nonane-4-carboxylate according to claim 2 , the powder X-ray diffractogram of which comprises at least three of the following characteristic lines:

Peak

Angle

Angström

2-theta°

d = 20.46

4.3

d = 10.26

8.6

d = 6.85

12.9

d = 4.70

18.9

d = 4.47

19.8

d = 3.52

25.2.

5. The fumarate salt of 4-bromophenyl 1,4-diazabicyclo[3.2.2]nonane-4-carboxylate according to claim 2 having a melting point of 176° C.+/−2° C. and a mean enthalpy of 107 J/g+/−2 J/g.

6. The fumarate salt of 4-bromophenyl 1,4-diazabicyclo[3.2.2]nonane-4-carboxylate according to claim 1 , wherein it is in the crystalline polymorphic form II.

7. The fumarate salt of 4-bromophenyl 1,4-diazabicyclo[3.2.2]nonane-4-carboxylate according to claim 6 , the infrared spectrum of which exhibits at least three of the following characteristic absorption bands:

λ (cm −1 )

2952

1721

1484

1200

 638.

8. The fumarate salt of 4-bromophenyl 1,4-diazabicyclo[3.2.2]nonane-4-carboxylate according to claim 6 , the powder X-ray diffractogram of which comprises at least three of the following characteristic lines:

Peak

Angle

Angström

2-theta°

d = 14.76

6.0

d = 9.54

9.3

d = 8.75

10.1

d = 4.75

18.7

d = 3.79

23.5

d = 3.69

24.1.

9. The fumarate salt of 4-bromophenyl 1,4-diazabicyclo[3.2.2]nonane-4-carboxylate according to claim 6 , having a melting point of 175° C.+/−2° C. and a mean enthalpy of 109 J/g+/−2 J/g.

10. A process for the preparation of the fumarate salt of 4-bromophenyl 1,4-diazabicyclo[3.2.2]nonane-4-carboxylate, form I, according to claim 2 , comprising reacting 4-bromophenyl 1,4-diazabicyclo[3.2.2]nonane-4-carboxylate in the free base form with fumaric acid in a solvent.

11. A process for the preparation of the fumarate salt of 4-bromophenyl 1,4-diazabicyclo[3.2.2]nonane-4-carboxylate, form II, according to claim 6 , comprising bringing the fumarate salt of 4-bromophenyl 1,4-diazabicyclo[3.2.2]nonane-4-carboxylate, form I, together with the fumarate salt of 2,4-dibromophenyl 1,4-diazabicyclo[3.2.2]nonane-4-carboxylate in a solvent.

12. A pharmaceutical composition comprising, as active principle, the fumarate salt of 4-bromophenyl 1,4-diazabicyclo[3.2.2]nonane-4-carboxylate according to claim 1 , and at least one pharmaceutically acceptable excipient.

13. A method of treating a disorder related to a dysfunctioning of the nicotinic receptors in a patient comprising administering to the patient an effective dose of the fumarate salt of 4-bromophenyl 1,4-diazabicyclo[3.2.2]nonane-4-carboxylate according to claim 1 ; wherein said disorder is selected from the group consisting of detrimental memory changes, disorder of the executive functions related to Alzheimer's disease, age associated memory impairment, senile dementia, Parkinsonian syndrome, trisomy 21, cognitive impairment associated with schizophrenia or post-traumatic stress disorder, Korsakoff's alcoholic syndrome, vascular dementia, cranial trauma, motor disorders observed in Parkinson's disease; multiple sclerosis, stroke, cerebral hypoxic episode, positive and/or negative symptoms of schizophrenia, bipolar disorder, depression, anxiety, panic attacks, attention deficit hyperactivity disorder, obsessive-compulsive behavior, symptoms due to weaning from dependence-inducing substances, pain, lower limb ischemia, lower limb arterial occlusive disease, cardiac ischemia, myocardial infarction, cardiac insufficiency, skin healing deficiency in diabetic patients, varicose ulcers of venous insufficiency, septic shock, inflammation, psoriasis, asthma, and ulcerative colitis.

14. The method according to claim 13 wherein the disorder is a disorder of the executive functions related to Alzheimer's disease.

15. The method according to claim 13 wherein the disorder is cognitive impairment associated with schizophrenia.